Introduction This Phase I trial aimed to determine the maximum-tolerated-dose of erlotinib
administered with two standard chemoradiotherapy regimens for non-small cell lung cancer …

Purpose This study investigated whether sequential administration of erlotinib and
chemotherapy improves clinical outcomes versus chemotherapy alone in unselected …

Introduction: Erlotinib improves survival in patients with advanced non-small cell lung cancer
who have been previously treated with systemic chemotherapy. The current trial was …

Purpose To test, in a single-arm, prospective, phase 2 trial, whether adding the epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib to concurrent …

Purpose Although many studies have confirmed the synergic effects of combining
chemotherapy (CT) and radiotherapy (RT), clinical data evaluating safety and efficacy of …

8031 Background: Concurrent administration of EGFR TKIs and chemotherapy in 1st line
failed to improve survival. Preclinical data suggested potential antagonism due to TKI …

7020 Background: Majority of non-small cell lung cancer (NSCLC) overexpress EGFR. Our
prospective phase II trial investigated EGFR-TKI (erlotinib) as a radiosensitizer for …

7073 Background: Erlotinib (TarcevaTM) is an orally available selective EGFR tyrosine-
kinase inhibitor. In patients with advanced NSCLC, 2nd/3rd-line erlotinib significantly …

Background Erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) is an oral, epidermal
growth factor receptor tyrosine kinase inhibitor that has antitumor activity and good …

Purpose: Erlotinib has proven activity in pretreated patients with advanced non–small cell
lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC …